Amica Mutual Insurance Co. Sells 2,162 Shares of Johnson & Johnson (NYSE:JNJ)

Amica Mutual Insurance Co. lowered its stake in Johnson & Johnson (NYSE:JNJ) by 3.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 65,861 shares of the company’s stock after selling 2,162 shares during the quarter. Johnson & Johnson accounts for 1.0% of Amica Mutual Insurance Co.’s portfolio, making the stock its 22nd biggest position. Amica Mutual Insurance Co.’s holdings in Johnson & Johnson were worth $9,525,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Principal Financial Group Inc. increased its stake in shares of Johnson & Johnson by 10.5% during the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock valued at $562,723,000 after buying an additional 329,473 shares during the period. United Bank increased its position in Johnson & Johnson by 5.6% during the 3rd quarter. United Bank now owns 3,788 shares of the company’s stock valued at $614,000 after purchasing an additional 202 shares during the period. Algert Global LLC bought a new position in Johnson & Johnson in the 3rd quarter worth $721,000. Loomis Sayles & Co. L P lifted its position in shares of Johnson & Johnson by 44.2% in the 3rd quarter. Loomis Sayles & Co. L P now owns 87,611 shares of the company’s stock worth $14,198,000 after purchasing an additional 26,869 shares during the period. Finally, Townsquare Capital LLC boosted its stake in shares of Johnson & Johnson by 12.9% during the 3rd quarter. Townsquare Capital LLC now owns 123,812 shares of the company’s stock valued at $20,065,000 after purchasing an additional 14,185 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have commented on JNJ shares. Raymond James lowered their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Bank of America lifted their price target on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research report on Wednesday, March 5th. Leerink Partners decreased their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Stifel Nicolaus dropped their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Finally, Citigroup lowered their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $171.33.

Johnson & Johnson Stock Up 0.4 %

Johnson & Johnson stock opened at $161.64 on Thursday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The stock has a fifty day simple moving average of $158.04 and a two-hundred day simple moving average of $156.18. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The firm has a market cap of $389.54 billion, a price-to-earnings ratio of 24.31, a PEG ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the company earned $2.29 EPS. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.07%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.